Skyrocketing Spending: Medicare’s $5.7 Billion Investment in GLP-1 Drugs Sparks Debate on Healthcare Costs and Obesity Treatment
In a striking testament to the burgeoning demand for innovative healthcare solutions, Medicare’s expenditure on GLP-1 medications like Ozempic, Wegovy, and Mounjaro soared to an
Read More